Silent ischemia: clinical relevance
C Richard Conti1, Anthony A Bavry, John W Petersen
1Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
Insights
Silent ischemia, or myocardial ischemia without symptoms, is common in coronary artery disease. While past studies suggested revascularization benefits, current optimal medical therapy may be equally effective for preventing cardiovascular events.
Area of Science:
- Cardiology
- Ischemic Heart Disease
- Clinical Trials
Background:
- Asymptomatic (silent) ST-segment depression is more frequent than symptomatic ischemia in coronary artery disease patients.
- Silent ischemia independently predicts adverse cardiovascular outcomes.
- Early studies like ACIP suggested revascularization superiority over medical therapy for silent ischemia.
Purpose of the Study:
- To evaluate the current role of silent ischemia in risk stratification for cardiovascular events.
- To discuss the implications of recent trial data on managing silent ischemia.
- To identify future research directions for silent ischemia, particularly in heart transplant recipients.
Main Methods:
- Review of findings from the Asymptomatic Cardiac Ischemia Pilot Study (ACIP).
- Analysis of results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
- Discussion of current treatment paradigms for coronary artery disease.
Main Results:
- The COURAGE trial indicated similar cardiovascular event rates between optimal medical therapy alone and revascularization plus optimal medical therapy.
- Current medical therapy appears as effective as revascularization in managing symptomatic ischemia and preventing cardiovascular events.
- Silent ischemia may persist despite current treatments and could still signify elevated cardiovascular risk.
Conclusions:
- In the current era, optimal medical therapy is as effective as revascularization for preventing cardiovascular events.
- Silent ischemia may remain a significant risk factor, even with optimal medical management.
- Further research is needed to explore management strategies for persistent silent ischemia, especially in heart transplant patients, and to evaluate newer therapies.
Abstract:
Myocardial ischemia can occur without overt symptoms. In fact, asymptomatic (or silent) ST-segment depression during ambulatory electrocardiogram monitoring occurs more often than symptomatic ST-segment depression in patients with coronary artery disease. Initial studies documented that silent ischemia provided independent prediction of adverse outcomes in patients with known and unknown coronary artery disease. The ACIP (Asymptomatic Cardiac Ischemia Pilot Study) enrolled patients in the 1990s and found that revascularization was better than medical therapy in reducing silent ischemic episodes and possibly cardiovascular (CV) events. However, the more recent COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial found similar CV event rates between patients treated with optimal medical therapy alone and those treated with optimal medical therapy plus percutaneous revascularization. Therefore, in the current era, medical therapy appears to be as effective as revascularization in suppressing symptomatic ischemia and preventing CV events. COURAGE was not designed to evaluate changes in the frequency of silent ischemia. Therefore, silent ischemia may persist despite current-era treatment and might still identify patients with increased risk of CV events. Also, silent ischemia is likely to occur frequently in heart transplant patients with denervated hearts and coronary allograft vasculopathy, and future study aimed at improving the management of silent ischemia in this population is warranted. Additionally, future research is warranted to study the effect of newer medical therapies such as ranolazine or selected use of revascularization (for example, guided by fractional flow reserve) in those patients with persistent silent ischemia despite optimal current-era medical therapy.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Ischemic Stroke l: Introduction
Angina II: Classification
Transient Ischemic Attack l: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations


